U.S. stock futures tumbled Sunday night, extending a volatile start to 2026 as a historic collapse in gold and silver prices and a sharp downturn in Bitcoin sparked fears of a broader market deleveraging.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
A woman identifying herself as Justin Sun's former partner has leveled serious market manipulation claims against the Tron founder, alleging he used employee-linked Binance accounts to inflate TRX's price during the 2017-2018 crypto boom before cashing out, leaving retail investors holding the bag.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
As regional markets navigate post-oil volatility and geopolitical shifts, a closer look reveals three penny stocks—from Turkish media to Saudi healthcare—that combine resilient balance sheets with high-risk, high-reward potential for the discerning investor.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
Samsung Electronics has launched a special edition Galaxy Z Flip7 for the 2026 Winter Olympics, packed with AI-powered translation and athlete-centric features, while also previewing new on-screen privacy controls designed to thwart 'shoulder surfing'. These dual announcements underscore the tech giant's push to blend high-profile partnerships with user-centric innovation as it seeks to differentiate in a competitive market.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
Kalshi's parlay betting, newly accessible via Robinhood, generated unprecedented single-day fee revenue last Sunday, surpassing the platform's historical earnings from all non-sports events combined and signaling a major shift in the prediction market landscape.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
Asian equities staged a strong recovery on Tuesday, with South Korea's Kospi and Japan's Nikkei leading gains as investors returned to tech stocks. The rebound follows recent volatility, with markets now focused on corporate earnings and geopolitical risks.
Amid a challenging home furnishings market, luxury retailer RH is posting resilient results and gaining ground on competitors. A closer look reveals a strategy pivoting on international expansion, high-margin experiential offerings, and disciplined inventory management, setting the stage for ambitious long-term growth.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
UEM Sunrise Berhad (KLSE:UEMS) has emerged as a top performer on the Kuala Lumpur Stock Exchange in recent weeks, reigniting interest in the Malaysian property developer. However, our analysis suggests the stock may now be trading above its intrinsic value, prompting a critical look at its future growth prospects and the sustainability of its current momentum.
Samsung Electronics unveils enhanced privacy controls for Galaxy devices and a special Olympic Edition of its foldable phone, aiming to bolster its brand in security and high-profile partnerships while its shares show significant long-term gains.
All eyes are on healthcare giant McKesson as it prepares to report fourth-quarter results. With a history of revenue misses and a slowing growth rate, analysts and investors are keen to see if the company can deliver a positive surprise.
